Updates on Human Immunodeficiency Virus (HIV) by Martinez Sanchez, Eduardo
Baptist Health South Florida 
Scholarly Commons @ Baptist Health South Florida 
All Publications 
1-11-2020 
Updates on Human Immunodeficiency Virus (HIV) 
Eduardo Martinez Sanchez 
Homestead Hospital, Eduardomar4@baptisthealth.net 
Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications 
 Part of the Pharmacy and Pharmaceutical Sciences Commons, and the Virus Diseases Commons 
Citation 
Martinez Sanchez, Eduardo, "Updates on Human Immunodeficiency Virus (HIV)" (2020). All Publications. 
3380. 
https://scholarlycommons.baptisthealth.net/se-all-publications/3380 
This Conference Lecture -- Open Access is brought to you for free and open access by Scholarly Commons @ 
Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator 
of Scholarly Commons @ Baptist Health South Florida. For more information, please contact 
Carrief@baptisthealth.net. 
Updates on Human 
Immunodeficiency 
Virus (HIV)
Eduardo Martinez, Pharm.D.
PGY-1 Pharmacy Resident 
Homestead Hospital, BHSF 1
Objectives 
 Provide an overview on HIV /AIDS
 Review current antiretroviral treatment strategies 
 Recognize recently approved and emerging pipeline 
agents for the treatment of HIV 
 Summarize the most recent guideline updates for the 
treatment of HIV/AIDS 
 Discuss the role of the pharmacist in the treatment of 
HIV 
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Abbreviations 
 AIDS – Acquired Immune Deficiency Syndrome
 ART – Anti-Retroviral Therapy
 CD4 – Cluster of Differentiation 4
 CDC – Centers for Disease Control and Prevention
 CCR5 – CC Chemokine Receptor 5
 GP120 – Glycoprotein 120
 HIV – Human Immunodeficiency Virus
 INSTI – Integrase Strand Transfer Inhibitor 
 MOA – Mechanism of Action
 MSM – Men who have Sex with Men
 NNRTI – Non-Nucleoside Reverse Transcriptase Inhibitor
 NRTI – Nucleoside Reverse Transcriptase Inhibitor
 PEP – Post-Exposure Prophylaxis
 PI – Protease Inhibitor 
 PrEP – Pre-Exposure Prophylaxis
 STD – Sexually Transmitted Disease
 STR – Single Tablet Regimen 
 VL – Viral Load 3
Background  
HIV attacks the body’s immune system, specifically 
the CD4 cells (T cells). 
HIV interferes with the body's ability to fight infection, 
making a person more vulnerable to other diseases.
The outlook for people living with HIV has significantly 
improved over the past two decades.
Without treatment, HIV infection is likely to develop 
into AIDS as the immune system gradually wears 
down.
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Course of HIV
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Source: Centers for Disease Control and Prevention 
Risk of Exposure  
Source: Centers for Disease Control and Prevention. 
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https://cghealth.com/topics/hiv-testing/
Transmission 
Source: Centers for Disease Control and Prevention 7
Decrease Percent Infection by Transmission Route 
Diagnosis
HIV Testing:
 4th generation antigen/antibody combination test 
 Highly infectious acute stage 
 p24 
 Newly infected individuals
AIDS Diagnosis :
 A positive test for HIV antibodies or antigen and one 
or more of the following:
 CD4 T cells <200 (or CD4 percentage <14%), 
or 
 Any of the 25 “AIDS defining conditions”
Source: US DHHS. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents. 2019 8
Diagnosis
Source: US DHHS. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents. 2019 9
• In-vitro diagnostic home-
use test 
• Pain-free testing with oral 
fluid
• Detects HIV infection if 
used 3 months after a risk 
event
OraQuick HIV Test
Epidemiology
 Approximately 1.1 million people in the U.S. are living 
with HIV today
 About 15% of them are unaware they are infected
 An estimated 39,000 Americans became newly 
infected with HIV in 2016
 Gay, bisexual, and other MSM bear the greatest 
burden by risk group
 26,000 of new HIV infections per year
Source: Centers for Disease Control and Prevention 
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HIV Diagnoses 
 In 2017, 38,739 people received an HIV diagnosis in 
the U.S.
Source: Centers for Disease Control and Prevention 
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HIV Incidence
Source: Centers for Disease Control and Prevention 
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HIV in the U.S.
Source: cdc.gov/HIV/statistics/overview/geographic distribution
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HIV in Florida  
Source: cdc.gov/nchhstp/stateprofiles/pdf/florida_profile
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Nationwide Initiative
Ending the HIV Epidemic: A Plan for America
Key strategies:
 Diagnosing all individuals with HIV as early as 
possible after infection.
 Treating HIV rapidly and effectively after diagnosis to 
achieve sustained viral suppression.
 Protecting individuals at risk for HIV using proven 
prevention approaches.
 Responding rapidly to detect and respond to growing 
HIV clusters and prevent new infections.
Source: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview 
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A Plan for America 
Source: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview 
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True or False 
Antiretroviral therapy is recommended for all HIV 
positive patients regardless of CD4 count to reduce 
morbidity, mortality, and transmission.
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True or False 
18
Antiretroviral therapy is recommended for all HIV 
positive patients regardless of CD4 count to reduce 
morbidity, mortality, and transmission.
ART
Rapid ART initiation, including starting ART on the same day 
as HIV diagnosis, can lead to improved clinical outcomes.
Source: The INSIGHT START Study Group. N Engl J Med. 2015;373:795-807.
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HIV Transmission 
Transmission of HIV Infection in 2016 
Source: Centers for Disease Control and Prevention 
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Source :https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/19/73/the-hiv-life-cycle
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True or False 
The initiation of a regimen containing two non-
nucleoside reverse transcriptase inhibitors (NNRTIs) is 
common and recommended in HIV patients. 
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True or False 
The initiation of a regimen containing two non-
nucleoside reverse transcriptase inhibitors (NNRTIs) is 
common and recommended in HIV patients. 
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Therapy 
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INSTI
Dolutegravir 
(DTG)-TIVICAY 
Raltegravir (RAL)-
ISENTRESS
Elvitegravir(EVG)-
VITEKTA
Bictegravir (BIC)
Therapy 
 Integrase inhibitor based regimens are recommended for 
most patients. 
25Sources: US DHHS. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents. 2019.
Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas, NV. 2019.
Agent Advantages Disadvantages
Dolutegravir • Few drug interactions
• Single-tablet formulation
• Higher barrier to resistance
• May be use during pregnancy 
• Co-formulated with abacavir 
and lamivudine
• Risk of neural tube defects 
Bictegravir • Few drug interactions
• Single-tablet formulation
• Higher barrier to resistance
• Lack of data in pregnancy 
Raltegravir • Few drug interactions
• Preferred ARV in pregnancy
• Not available as a single-tablet 
formulation
• Lower barrier to resistance
Elvitegravir • Single-tablet formulation 
• Can be used for rapid ART start
• Lower barrier to resistance
• Avoid in pregnancy 
• (inadequate drug levels in the 
2nd/3rd trimesters)
Single Tablet Regimen
 Biktarvy- bictegravir/ emtricitabine/TAF (INSTI + 2 NRTIs)
 Triumeq- abacavir/dolutegravir/lamivudine (INSTI + 2 NRTIs)
 Atripla- efavirenz/tenofovir/TDF (NNRTI + 2 NRTIs)
 Stribild- elvitegravir/cobicistat/emtricitabine/TDF (boosted 
INSTI + 2 NRTIs)
 Genvoya- elvitegravir/cobicistat/emtricitabine/TAF (boosted 
INSTI + 2 NRTIs)
 Complera- emtricitabine/ rilpivirine/ TDF (NNRTI + 2 NRTIs)
 Odefsey- emtricitabine/ rilpivirine/ TAF (NNRTI + 2 NRTIs) 
 Symfi- efavirenz/lamivudine/TDF (NNRTI + 2 NRTIs)
 Symtuza- darunavir/cobicistat/emtricitabine/ TAF (boosted PI 
+ 2 NRTIs)
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Individualized Treatment   
Among a sample of HIV patients, incidence of 
comorbidities increased (2003 to 2013):   
 Hypertension rose from 11.6% to 25% 
 Hyperlipidemia rose from 9.5% to 21.9%
 Diabetes rose from 6.4% to 9.4%
Must consider the patient’s entire medical 
history when recommending or prescribing ART.
Source: Gallant J, et al. JID, Volume 216, Issue 12, 15 December 2017, Pages 1525–1533
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Individualized Treatment 
Condition Consider Avoiding Rationale
Dementia Efavirenz Potential overlap of 
symptoms
Opioid
dependence
Efavirenz May precipitate 
withdrawal 
Cardiovascular 
(CV) Risk
Abacavir, lopinavir/ritonavir Increased CV risk
Dyslipidemia Boosted protease inhibitors, 
efavirenz, elvitegravir/cobicistat, 
tenofovir disoproxil fumarate (TDF) 
Increased lipids
Source: Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas 2019 28
Individualized Treatment   
Condition Consider Avoiding Rationale
Chronic kidney 
disease (CrCl ≤ 
60 mL/min)
Tenofovir disoproxil fumarate 
(TDF) unless end stage renal 
disease (ESRD)
Risk of proximal renal 
tubulopathy 
Cirrhotic liver 
disease
Abacavir,
Symfi®(efavirenz/lamivudine/ 
TDF), atazanavir, darunavir, 
elvitegravir
Not recommended in 
severe liver disease
Osteoporosis Tenofovir disoproxil fumarate 
(TDF) 
Risk of decreasing bone 
mineral density 
Psychiatric illness Efavirenz, rilpivirine Possible exacerbation of 
symptoms / suicidal risk 
Source: Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas 2019 29
New Agents
Recently approved ART and agents in the pipeline:
30
Doravirine 
MOA:
 Non-nucleoside reverse transcriptase inhibitor 
Dose:
 100 mg orally daily 
Adverse Effects:
 Fatigue, nausea, headache 
Points to consider:
 Concern with neuropsychic and lipid abnormalities 
 STR: Delstrigo ( TDF + 3TC + DOR)
Source: Orkin C, et al. CID 2019: 68:535-44 31
Ibalizumab 
MOA:
 Binds to CD4 and interferes with post-attachment 
Dose:
 2000 mg intravenous (IV) loading dose
 800 mg IV every 14 days 
Adverse Effects:
 Infusion reactions, rash, dizziness, diarrhea 
Points to consider:
 Monoclonal antibody 
 For use in salvage therapy
 Miss dose > 3 days, restart cycle with loading dose  
Source: Trogarzo Product Package Insert. http://trogarzo.com/ 32
BNAbs
Body Neutralizing Antibodies (BNAbs) 
 Passive immunity 
 Use alone or a combination 
 Instant protection 
 Must be regularly “re-dosed” to maintain protection
BNAbs trials could be an important step toward 
designing an HIV vaccine.
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Pipeline Agents  
Lerinomab (PRO140 )
MOA: 
 Humanized monoclonal antibody that blocks entry via 
CCR5 binding 
Likely place in therapy: 
 Salvage, switch after oral
Points to consider: 
 Weekly subcutaneous (subQ) injections 
 High viral rebound at various doses 
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Pipeline Agents  
UB-421
MOA
 Broadly neutralizing monoclonal antibody targeting 
CD4 binding 
Likely place in therapy: 
 Treatment failure 
Points to consider:
 Weekly or 2 times weekly subQ injections 
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Pipeline Agents  
Fostemsavir
MOA: 
 Attachment inhibitor binds to GP 120
Dose:
 600 mg orally twice daily  
Adverse effects:
 Nausea, diarrhea, immune reconstitution inflammatory 
syndrome (IRIS), fatigue 
Likely place in therapy: 
 Salvage
BRIGHTE Week 96 Update (2019) 
Source: DHHS AIDSInfo https://aidsinfo.nih.gov/drugs/508/fostemsavir/0/professional 
36
Pipeline Agents  
Cabotegravir/rilpivirine
MOA: 
 Integrase strand transfer inhibitor + non-nucleoside 
reverse transcriptase inhibitor 
Dose:
 30 mg/25 mg orally daily for 4 weeks, then 400/600 
mg intramuscularly (IM) monthly 
Adverse effects:
 Nausea, injection site reaction, fatigue, pyrexia 
Likely place in therapy: 
 Under study for treatment naïve patients and PrEP
Source: Swindells S. CROI 2019, Abstract 1475 & Orkin C, CROI 2019, Abstract 3947 
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Pipeline Agents  
Cabotegravir/rilpivirine
Source: Swindells S. CROI 2019, Abstract 1475 & Orkin C, CROI 2019, Abstract 3947 38
PrEP vs. PEP 
Source: Centers for Disease Control and Prevention: US Public Health Service: Pre-exposure prophylaxis for the prevention of HIV infection in the United States—2017 
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PrEP: STD in the past 6 months
PrEP vs. PEP 
Source: Centers for Disease Control and Prevention: US Public Health Service: Pre-exposure prophylaxis for the prevention of HIV infection in the United States—2017 
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 Pre-Exposure Prophylaxis (PrEP)
• Truvada -TDF /emtricitabine
• Descovy - TAF / emtricitabine 
 Post-Exposure Prophylaxis (PEP)
 Truvada -TDF /emtricitabine plus Raltegravir
Pre-Exposure Prophylaxis   
Over 1 million Americans are at substantial risk for HIV, 
but only 90,000 PrEP prescriptions were filled in 2015 
Rodger AJ, et al. JAMA. 2016;316:171-181. Rodger A, et al. IAS 2018.
41Sources: Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas 2019
True or False  
The new Guidelines for the Use of Antiretroviral Agents 
in Adults and Adolescents with HIV suggest screening for 
substance abuse disorders as routine part of clinical 
care.
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True or False  
The new Guidelines for the Use of Antiretroviral Agents 
in Adults and Adolescents with HIV suggest screening for 
substance abuse disorders as routine part of clinical 
care.
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Updates (Dec 18th)
DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 
Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf 
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Updates (Dec 18th)
Treatment as prevention (TasP), commonly known as 
Undetectable = Untransmittable or U = U.
 Using effective ART to consistently suppress plasma 
HIV RNA levels to <200 copies/mL.
 Use another form of prevention with sexual partners 
for at least the first 6 months of treatment and until 
HIV RNA <200 copies/mL.
DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 
Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf 
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Updates (Dec 18th)
Dolutegravir Recommendations for Individuals of 
Childbearing Potential
 Prevalence of neural tube defects is lower than 
initially reported (the rate has been reduced from 
0.9% to 0.3%).
 DTG may be used as an alternative ART for individuals 
who are of childbearing potential and trying to 
conceive.
DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 
Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf 
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Updates (Dec 18th)
Laboratory Testing for Initial Assessment and Monitoring 
of People with HIV Receiving Antiretroviral Therapy
 The panel previously recommended monitoring fasting 
lipid profile and fasting glucose before and after 
initiation of ART.
 The new recommendation allows for random (non-
fasting) tests.
DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 
Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf 
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Updates (Dec 18th)
DTG/3TC was added to the list of Recommended Initial 
Regimens for Most People with HIV, except for 
individuals:
 With pre-treatment HIV RNA >500,000 copies/mL
 Who are known to have active hepatitis B virus (HBV) 
co-infection
DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 
48Source: Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas, NV. 2019.
Updates (Dec 18th)
Tables
 Common and/or Severe Adverse Effects Associated 
with Antiretroviral Therapy
 Antiretroviral Therapy-Associated Adverse Events That 
Can Be Managed with Substitution of Alternative 
Antiretroviral Agent
Source: aidsinfo.nih.gov/guidelines. 
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Pharmacist’s Role
Source: Amico KR, et al. J Int Assoc Provid AIDS Care. 2013;12:79-83.
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 Empower patients to get tested.
 Identify opportunities to increase compliance.
 Recommend strategies to protect high risk 
individuals.
 Get involved !!!! 
Conclusion 
Breakthroughs notwithstanding, HIV/AIDS research has not 
slowed.
Despite the progress achieved in the last few decades, HIV 
incidence remains high throughout the US.
Science has provided us the tools to target a goal of reducing 
new HIV diagnosis by more than 90% in 10 years.
Pharmacists are uniquely positioned to contribute to this goal. 
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